Alpna Seth, Director at Keros Therapeutics, Inc. (KROS), sold 2,625 shares at $10.72 ($28K) on 2026-06-04, disclosed to the SEC on 2026-06-05.
Scheduled sale ($28k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.